India, Feb. 10 -- Pharma major Venus Remedies on Monday said it has received marketing authorization from Indonesia for its Enoxaparin, an anticoagulant, in pre-filled syringes across all major strengths.
This approval reinforces the company's presence in Indonesia and aligns with its broader expansion strategy in Southeast Asia, a company statement said here.
"Indonesia has the highest burden of cardiovascular diseases in the region, driven by an aging population and lifestyle changes. Our Enoxaparin will offer a cost-effective solution to manage clot-related conditions," said Saransh Chaudhary, president, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre
Published by HT Digital Content Services with permissi...